Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007030321 | Stomach | CSG | negative regulation of stress-activated protein kinase signaling cascade | 10/1034 | 51/18723 | 4.07e-04 | 6.51e-03 | 10 |
GO:000724921 | Stomach | CSG | I-kappaB kinase/NF-kappaB signaling | 30/1034 | 281/18723 | 4.30e-04 | 6.76e-03 | 30 |
GO:00427422 | Stomach | CSG | defense response to bacterium | 35/1034 | 350/18723 | 5.14e-04 | 7.88e-03 | 35 |
GO:00439032 | Stomach | CSG | regulation of biological process involved in symbiotic interaction | 12/1034 | 72/18723 | 5.38e-04 | 8.02e-03 | 12 |
GO:00096152 | Stomach | CSG | response to virus | 36/1034 | 367/18723 | 6.16e-04 | 8.96e-03 | 36 |
GO:004312321 | Stomach | CSG | positive regulation of I-kappaB kinase/NF-kappaB signaling | 22/1034 | 186/18723 | 6.21e-04 | 9.00e-03 | 22 |
GO:00326122 | Stomach | CSG | interleukin-1 production | 17/1034 | 128/18723 | 6.80e-04 | 9.58e-03 | 17 |
GO:00326522 | Stomach | CSG | regulation of interleukin-1 production | 17/1034 | 128/18723 | 6.80e-04 | 9.58e-03 | 17 |
GO:00019062 | Stomach | CSG | cell killing | 22/1034 | 188/18723 | 7.18e-04 | 1.00e-02 | 22 |
GO:00027642 | Stomach | CSG | immune response-regulating signaling pathway | 43/1034 | 468/18723 | 7.58e-04 | 1.04e-02 | 43 |
GO:006102821 | Stomach | CSG | establishment of endothelial barrier | 9/1034 | 46/18723 | 7.99e-04 | 1.09e-02 | 9 |
GO:00603262 | Stomach | CSG | cell chemotaxis | 31/1034 | 310/18723 | 1.04e-03 | 1.33e-02 | 31 |
GO:00313412 | Stomach | CSG | regulation of cell killing | 14/1034 | 99/18723 | 1.06e-03 | 1.34e-02 | 14 |
GO:200037721 | Stomach | CSG | regulation of reactive oxygen species metabolic process | 19/1034 | 157/18723 | 1.08e-03 | 1.35e-02 | 19 |
GO:00026882 | Stomach | CSG | regulation of leukocyte chemotaxis | 16/1034 | 122/18723 | 1.11e-03 | 1.37e-02 | 16 |
GO:007169221 | Stomach | CSG | protein localization to extracellular region | 35/1034 | 368/18723 | 1.25e-03 | 1.50e-02 | 35 |
GO:00018192 | Stomach | CSG | positive regulation of cytokine production | 42/1034 | 467/18723 | 1.32e-03 | 1.56e-02 | 42 |
GO:000315821 | Stomach | CSG | endothelium development | 17/1034 | 136/18723 | 1.35e-03 | 1.57e-02 | 17 |
GO:005122221 | Stomach | CSG | positive regulation of protein transport | 30/1034 | 303/18723 | 1.46e-03 | 1.68e-02 | 30 |
GO:005071421 | Stomach | CSG | positive regulation of protein secretion | 17/1034 | 137/18723 | 1.46e-03 | 1.68e-02 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2RL1 | SNV | Missense_Mutation | rs185549069 | c.308N>A | p.Arg103Gln | p.R103Q | P55085 | protein_coding | deleterious(0.04) | benign(0.103) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.946A>T | p.Ser316Cys | p.S316C | P55085 | protein_coding | tolerated(0.05) | possibly_damaging(0.882) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | insertion | Nonsense_Mutation | novel | c.703_704insCACATAAGTTAGCATAACATGCTAA | p.Leu235SerfsTer6 | p.L235Sfs*6 | P55085 | protein_coding | | | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | insertion | Frame_Shift_Ins | novel | c.947_948insAAATATTGATCTCTACATCCCCCAACACTCCA | p.Ser316ArgfsTer24 | p.S316Rfs*24 | P55085 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1076T>C | p.Leu359Pro | p.L359P | P55085 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2RL1 | SNV | Missense_Mutation | novel | c.998N>G | p.Ser333Cys | p.S333C | P55085 | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
F2RL1 | SNV | Missense_Mutation | novel | c.945N>C | p.Lys315Asn | p.K315N | P55085 | protein_coding | tolerated(0.26) | probably_damaging(0.913) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1018N>A | p.Asp340Asn | p.D340N | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1019N>G | p.Asp340Gly | p.D340G | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | | c.376N>G | p.Ile126Val | p.I126V | P55085 | protein_coding | tolerated(0.34) | benign(0.012) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ERYTHROMYCIN | ERYTHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | AC-55541 | CHEMBL493076 | 18720984 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100874 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ROXITHROMYCIN | ROXITHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 381744949 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103272 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103271 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100746 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103269 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103270 | | |